SBIR/STTR Research Award
Pseudotype Production Optimization
Award amount
$862,420Program and phase
SBIR · Phase IIAward year
2003Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- INTEGRAL MOLECULAR INC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- DY9KSWE8EJB8
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by applicant):
ViraCore is a tool-based biotechnology company that is creating a drug discovery platform for use by the pharmaceutical and biotechnology industries. ViraCore is developing "lipoparticles", nanometer-sized particles surrounded by a lipid bilayer and embedded with membrane-bound receptors, to purify and solubilize complex receptors from the cell surface while maintaining their structural integrity. ViraCore intends to leverage this technology for drug discovery and research of integral membrane proteins on biosensors and other microfluidic devices. Approximately half of the drugs in use today target membrane proteins, including G-protein coupled receptors. The purpose of this proposal is to scale lipoparticle production techniques, modify and improve lipoparticle properties, begin development of second-generation lipoparticles with unique capabilities, and validate lipoparticles for drug discovery applications. The goals of this proposal are to: - Optimize Commercial Manufacture Protocols - Develop Second- generation Lipoparticles - Improve Lipoparticle Composition - Validate Lipoparticles as Drug Screening Reagents
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- ANTIBODY REAGENTS FOR IMMUNOLOGIC ANALYSIS OF UNDER-REPRESENTED MAMMALIAN MODELS
- High-throughput Discovery of Antibodies against Understudied Membrane Proteins using mRNA
- Specificity Screening Drug Development Tool for Biotherapeutic Safety
- Development of Safe and Rapid Reporter Viruses for Studying Pathogenic and Pandemic Viruses
- Reagents for Immunologic Analysis of Under-represented Mammalian Models
Research funding history
48 SBIR/STTR records share this UEI (2002–2025). Reported award amounts total $32,839,788. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services